Skip to main navigation Skip to search Skip to main content

Clinical Benefit of Fixed-Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia

  • Chia Pin Lin
  • , Tzyy Jer Hsu
  • , Ying Chang Tung
  • , Fu Chih Hsiao
  • , Shing Hsien Chou
  • , Yu Sheng Lin
  • , Shao Wei Chen
  • , Pao Hsien Chu*
  • *Corresponding author for this work
  • Chang Gung University
  • National Tsing Hua University
  • Chang Gung Memorial Hospital

Research output: Contribution to journal › Journal Article › peer-review

6 Scopus citations

Abstract

BACKGROUND: Hypertension and hypercholesterolemia are important risk factors for cardiovascular disease, and treatment with fixed-dose combination (FDC) regimens is recommended by current guidelines. However, the clinical outcomes of different FDC dosages remain unknown. This study aimed to examine the clinical outcomes of FDC regimens and the free combination of amlodipine and atorvastatin at different dosages. METHODS AND RESULTS: Patients with concurrent hypertension and hypercholesterolemia treated daily with an FDC of 5 mg amlodipine and 10 mg atorvastatin (5/10 fixed group), and FDC of 5 mg amlodipine and 20 mg atorvastatin (5/20 fixed group), or free combination of 5 mg amlodipine and 20 mg atorvastatin (5/20 free group) were identified from the National Health Insurance Research Database of Taiwan. The primary outcome was the composite cardiovascular outcomes, including cardiovascular death, acute myocardial infarction, stroke, and coronary intervention. A total of 9095 patients were eligible for inclusion. The incidence of primary outcome per 1000 person-years was 16.6 in the 5/10 fixed group, 12.6 in the 5/20 fixed group, and 16.5 in the 5/20 free group (5/20 fixed versus 5/20 free: hazard ratio [HR], 0.76 [95% CI, 0.64–0.91]; 5/20 fixed versus 5/10 fixed: HR, 0.76 [95% CI, 0.63–0.90]). CONCLUSIONS: Among patients with concomitant hypertension and hypercholesterolemia, treatment with an FDC of amlodi-pine and high-dose atorvastatin led to a lower risk of a composite of cardiovascular outcomes than treatment with the free combination or a similar FDC with a lower dose of atorvastatin.

Original languageEnglish
Article numbere033780
Pages (from-to)e033780
JournalJournal of the American Heart Association
Volume13
Issue number9
DOIs
StatePublished - 07 05 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • amlodipine
  • atorvastatin
  • fixed-dose combination
  • hypercholesterolemia
  • hypertension
  • Humans
  • Middle Aged
  • Pyrroles
  • Male
  • Calcium Channel Blockers/administration & dosage
  • Female
  • Retrospective Studies
  • Anticholesteremic Agents/administration & dosage
  • Hypertension/drug therapy
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
  • Antihypertensive Agents/administration & dosage
  • Atorvastatin/administration & dosage
  • Amlodipine/administration & dosage
  • Treatment Outcome
  • Hypercholesterolemia/drug therapy
  • Taiwan/epidemiology
  • Blood Pressure/drug effects
  • Aged
  • Heptanoic Acids
  • Drug Combinations

Fingerprint

Dive into the research topics of 'Clinical Benefit of Fixed-Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia'. Together they form a unique fingerprint.

Cite this